- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval ; volume:83 ; number:16 ; day:31 ; month:10 ; year:2023 ; pages:1543 ; date:11.2023
Drugs ; 83, Heft 16 (31.10.2023), 1543, 11.2023
- Classification
-
Recht
- Creator
-
Syed, Yahiya Y.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-023-01965-7
- URN
-
urn:nbn:de:101:1-2024012212102665531715
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Syed, Yahiya Y.
- SpringerLink (Online service)
Other Objects (12)
Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction: Eplontersen: First Approval
Correction: Zilucoplan: First Approval
Correction: Elacestrant: First Approval
Correction: Vorasidenib: First Approval
Approval and Certification of Ophthalmic AI Devices in the European Union
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Nedosiran: First Approval
Correction to: Lenacapavir: First Approval
Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction: Eplontersen: First Approval
Correction: Zilucoplan: First Approval
Correction: Elacestrant: First Approval
Correction: Vorasidenib: First Approval
Approval and Certification of Ophthalmic AI Devices in the European Union
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Nedosiran: First Approval
Correction to: Lenacapavir: First Approval
Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction: Eplontersen: First Approval
Correction: Zilucoplan: First Approval
Correction: Elacestrant: First Approval
Correction: Vorasidenib: First Approval
Approval and Certification of Ophthalmic AI Devices in the European Union
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Nedosiran: First Approval